Cargando…

A combination hepatoma-targeted therapy based on nanotechnology: pHRE-Egr1-HSV-TK/(131)I-antiAFPMcAb-GCV/MFH

Combination targeted therapy is a promising cancer therapeutic strategy. Here, using PEI-Mn(0.5)Zn(0.5)Fe(2)O(4) nanoparticles (PEI-MZF-NPs) as magnetic media for MFH (magnetic fluid hyperthermia) and gene transfer vector for gene-therapy, a combined therapy, pHRE-Egr1-HSV-TK/(131)I-antiAFPMcAb-GCV/...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Mei, Huang, Junxing, Jiang, Xingmao, Zhang, Jia, Yu, Hong, Ye, Jun, Zhang, Dongsheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5027595/
https://www.ncbi.nlm.nih.gov/pubmed/27642033
http://dx.doi.org/10.1038/srep33524
_version_ 1782454268397092864
author Lin, Mei
Huang, Junxing
Jiang, Xingmao
Zhang, Jia
Yu, Hong
Ye, Jun
Zhang, Dongsheng
author_facet Lin, Mei
Huang, Junxing
Jiang, Xingmao
Zhang, Jia
Yu, Hong
Ye, Jun
Zhang, Dongsheng
author_sort Lin, Mei
collection PubMed
description Combination targeted therapy is a promising cancer therapeutic strategy. Here, using PEI-Mn(0.5)Zn(0.5)Fe(2)O(4) nanoparticles (PEI-MZF-NPs) as magnetic media for MFH (magnetic fluid hyperthermia) and gene transfer vector for gene-therapy, a combined therapy, pHRE-Egr1-HSV-TK/(131)I-antiAFPMcAb-GCV/MFH, for hepatoma is developed. AntiAFPMcAb (Monoclonal antibody AFP) is exploited for targeting. The plasmids pHRE-Egr1-HSV-TK are achieved by incorporation of pEgr1-HSV-TK and pHRE-Egr1-EGFP. Restriction enzyme digestion and PCR confirm the recombinant plasmids pHRE-Egr1-HSV-TK are successfully constructed. After exposure to the magnetic field, PEI-MZF-NPs/pHRE-Egr1-EGFP fluid is warmed rapidly and then the temperature is maintained at 43 °C or so, which is quite appropriate for cancer treatment. The gene expression reaches the peak when treated with 200 μCi (131)I for 24 hours, indicating that the dose of 200 μCi might be the optimal dose for irradiation and 24 h irradiation later is the best time to initiate MFH. The in vitro and in vivo experiments demonstrate that pHRE-Egr1-HSV-TK/(131)I-antiAFPMcAb-GCV/MFH can greatly suppress hepatic tumor cell proliferation and induce cell apoptosis and necrosis and effectively inhibit the tumor growth, much better than any monotherapy does alone. Furthermore, the combination therapy has few or no adverse effects. It might be applicable as a strategy to treat hepatic cancer.
format Online
Article
Text
id pubmed-5027595
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-50275952016-09-22 A combination hepatoma-targeted therapy based on nanotechnology: pHRE-Egr1-HSV-TK/(131)I-antiAFPMcAb-GCV/MFH Lin, Mei Huang, Junxing Jiang, Xingmao Zhang, Jia Yu, Hong Ye, Jun Zhang, Dongsheng Sci Rep Article Combination targeted therapy is a promising cancer therapeutic strategy. Here, using PEI-Mn(0.5)Zn(0.5)Fe(2)O(4) nanoparticles (PEI-MZF-NPs) as magnetic media for MFH (magnetic fluid hyperthermia) and gene transfer vector for gene-therapy, a combined therapy, pHRE-Egr1-HSV-TK/(131)I-antiAFPMcAb-GCV/MFH, for hepatoma is developed. AntiAFPMcAb (Monoclonal antibody AFP) is exploited for targeting. The plasmids pHRE-Egr1-HSV-TK are achieved by incorporation of pEgr1-HSV-TK and pHRE-Egr1-EGFP. Restriction enzyme digestion and PCR confirm the recombinant plasmids pHRE-Egr1-HSV-TK are successfully constructed. After exposure to the magnetic field, PEI-MZF-NPs/pHRE-Egr1-EGFP fluid is warmed rapidly and then the temperature is maintained at 43 °C or so, which is quite appropriate for cancer treatment. The gene expression reaches the peak when treated with 200 μCi (131)I for 24 hours, indicating that the dose of 200 μCi might be the optimal dose for irradiation and 24 h irradiation later is the best time to initiate MFH. The in vitro and in vivo experiments demonstrate that pHRE-Egr1-HSV-TK/(131)I-antiAFPMcAb-GCV/MFH can greatly suppress hepatic tumor cell proliferation and induce cell apoptosis and necrosis and effectively inhibit the tumor growth, much better than any monotherapy does alone. Furthermore, the combination therapy has few or no adverse effects. It might be applicable as a strategy to treat hepatic cancer. Nature Publishing Group 2016-09-19 /pmc/articles/PMC5027595/ /pubmed/27642033 http://dx.doi.org/10.1038/srep33524 Text en Copyright © 2016, The Author(s) http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
spellingShingle Article
Lin, Mei
Huang, Junxing
Jiang, Xingmao
Zhang, Jia
Yu, Hong
Ye, Jun
Zhang, Dongsheng
A combination hepatoma-targeted therapy based on nanotechnology: pHRE-Egr1-HSV-TK/(131)I-antiAFPMcAb-GCV/MFH
title A combination hepatoma-targeted therapy based on nanotechnology: pHRE-Egr1-HSV-TK/(131)I-antiAFPMcAb-GCV/MFH
title_full A combination hepatoma-targeted therapy based on nanotechnology: pHRE-Egr1-HSV-TK/(131)I-antiAFPMcAb-GCV/MFH
title_fullStr A combination hepatoma-targeted therapy based on nanotechnology: pHRE-Egr1-HSV-TK/(131)I-antiAFPMcAb-GCV/MFH
title_full_unstemmed A combination hepatoma-targeted therapy based on nanotechnology: pHRE-Egr1-HSV-TK/(131)I-antiAFPMcAb-GCV/MFH
title_short A combination hepatoma-targeted therapy based on nanotechnology: pHRE-Egr1-HSV-TK/(131)I-antiAFPMcAb-GCV/MFH
title_sort combination hepatoma-targeted therapy based on nanotechnology: phre-egr1-hsv-tk/(131)i-antiafpmcab-gcv/mfh
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5027595/
https://www.ncbi.nlm.nih.gov/pubmed/27642033
http://dx.doi.org/10.1038/srep33524
work_keys_str_mv AT linmei acombinationhepatomatargetedtherapybasedonnanotechnologyphreegr1hsvtk131iantiafpmcabgcvmfh
AT huangjunxing acombinationhepatomatargetedtherapybasedonnanotechnologyphreegr1hsvtk131iantiafpmcabgcvmfh
AT jiangxingmao acombinationhepatomatargetedtherapybasedonnanotechnologyphreegr1hsvtk131iantiafpmcabgcvmfh
AT zhangjia acombinationhepatomatargetedtherapybasedonnanotechnologyphreegr1hsvtk131iantiafpmcabgcvmfh
AT yuhong acombinationhepatomatargetedtherapybasedonnanotechnologyphreegr1hsvtk131iantiafpmcabgcvmfh
AT yejun acombinationhepatomatargetedtherapybasedonnanotechnologyphreegr1hsvtk131iantiafpmcabgcvmfh
AT zhangdongsheng acombinationhepatomatargetedtherapybasedonnanotechnologyphreegr1hsvtk131iantiafpmcabgcvmfh
AT linmei combinationhepatomatargetedtherapybasedonnanotechnologyphreegr1hsvtk131iantiafpmcabgcvmfh
AT huangjunxing combinationhepatomatargetedtherapybasedonnanotechnologyphreegr1hsvtk131iantiafpmcabgcvmfh
AT jiangxingmao combinationhepatomatargetedtherapybasedonnanotechnologyphreegr1hsvtk131iantiafpmcabgcvmfh
AT zhangjia combinationhepatomatargetedtherapybasedonnanotechnologyphreegr1hsvtk131iantiafpmcabgcvmfh
AT yuhong combinationhepatomatargetedtherapybasedonnanotechnologyphreegr1hsvtk131iantiafpmcabgcvmfh
AT yejun combinationhepatomatargetedtherapybasedonnanotechnologyphreegr1hsvtk131iantiafpmcabgcvmfh
AT zhangdongsheng combinationhepatomatargetedtherapybasedonnanotechnologyphreegr1hsvtk131iantiafpmcabgcvmfh